nach oben

Current Obstetrics and Gynecology Reports

Erschienen in:

06.05.2023 | REVIEW

Second Trimester Medication Abortion Regimens and the Mifepristone-Misoprostol Dosing Interval

verfasst von: Emma M. Smith, Katherine Pocius, Jessica Atrio

Erschienen in: Current Obstetrics and Gynecology Reports | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this article is to review current methods of induction termination of pregnancy in the second trimester. The specific area of focus is recent publication regarding timing of mifepristone and misoprostol dosing. Current international guidelines recommend initial treatment with mifepristone followed by misoprostol after 24 to 48 h.

Recent Findings

Retrospective studies indicate that a shorter interval between mifepristone and misoprostol of less than 12 h or even concomitant administration may result in a shorter total abortion time without increasing risk of incomplete abortion or complications.

Summary

Given the potential benefit of increased efficacy, with successful expulsion of the pregnancy, and reduced time to delivery with shorter mifepristone-misoprostol intervals or concurrent administration practitioners should offer all second trimester medication abortion treatment with mifepristone. Further studies are needed to evaluate the implementation of concurrent or varied dosing intervals and the magnitude of benefit vs risks, with attention to the patient experience, resources, and costs.

Cohen MA, Kapp N, Edelman A. Abortion care beyond 13 weeks’ gestation: a global perspective. Clin Obstet Gynecol. 2021;64(3):460–74.CrossRefPubMed

Dodd JM, Crowther CA. Misoprostol for induction of labour to terminate pregnancy in the second or third trimester for women with a fetal anomaly or after intrauterine fetal death. Cochrane Database of Syst Rev 2010;4:CD004901. https://doi.org/10.1002/14651858.CD004901.pub2. Accessed 07 December 2022.

Abediasl Z, Sheikh M, Pooransari P, Farahani Z, Kalani F. Vaginal misoprostol versus intravenous oxytocin for the management of second-trimester pregnancies with intrauterine fetal death: a randomized clinical trial. J Obstet Gynaecol Res. 2016;42(3):246–51.CrossRefPubMed

The Care of Women Requesting Induced Abortion (Evidence-based Clinical Guideline No. 7). Royal College of Obstetricians & Gynaecologists (RCOG). November 2011, reaffirmed 2018.

Abortion care guideline. Geneva: World Health Organization (WHO); 2022. License: CC BY-NC-SA 3.0 IGO.

Anselem O, Jouannic JM, Winer N, Bouchghoul H, Vivanti AJ, Quibel T, Massardier J, Rousseau J, Ancel PY, Goffinet F, Tsatsaris V. Cervical dilators used concurrently with misoprostol to shorten labor in second-trimester termination of pregnancy: a randomized controlled trial. Obstet Gynecol. 2022 Sep 1;140(3):453–460. https://doi.org/10.1097/AOG.0000000000004887. Epub 2022 Aug 3. Erratum in: Obstet Gynecol. 2022;140(5):902. PMID:35,926,202.

Dickinson JE, Evans SF. A comparison of oral misoprostol with vaginal misoprostol administration in second-trimester pregnancy termination for fetal abnormality. Obstet Gynecol. 2003;101(6):1294–9.PubMed

Green J, Borgatta L, Sia M, Kapp N, Saia K, Carr-Ellis S, Vragovic O. Interventions rates for placental removal following induction abortion with misoprostol. Contraception. 2007;76(4):310–3.CrossRefPubMed

Berghella V, Airoldi J, O’Neill AM, Einhorn K, Hoffman M. Misoprostol for second trimester pregnancy termination in women with prior cesarean: a systematic review. BJOG. 2009;116:1151–7.CrossRefPubMed

10.

Borgatta L, Kapp N. Society of Family Planning. Clinical guidelines. Labor induction abortion in the second trimester Contraception. 2011;84(1):4–18. https://doi.org/10.1016/j.contraception.2011.02.005. Epub 2011 Mar 30. PMID:21664506.CrossRefPubMed

11.

Perritt JB, Burke A, Edelman AB. Interruption of nonviable pregnancies of 24–28 weeks’ gestation using medical methods: release date June 2013 SFP guideline #20,133. Contraception. 2013;88(3):341–9.CrossRefPubMed

12.

Vlad S, Boucoiran I, St-Pierre ÉR, Ferreira E. Mifepristone-misoprostol use for second- and third-trimester medical termination of pregnancy in a Canadian tertiary care centre. J Obstet Gynaecol Can. 2022;44(6):683–689. https://doi.org/10.1016/j.jogc.2021.12.010. Epub 2022 Feb 1. PMID:35,114,381.

13.

Wildschut H, Both MI, Medema S, Thomee E, Wildhagen MF, Kapp N. Medical methods for mid-trimester termination of pregnancy. Cochrane Database Syst Rev. 2011;2011(1):CD005216. https://doi.org/10.1002/14651858.CD005216.pub2. PMID:21,249,669; PMCID:PMC8557267.

14.

Prodan N, Breisch J, Hoopmann M, Abele H, Wagner P, Kagan KO. Dosing interval between mifepristone and misoprostol in second and third trimester termination. Arch Gynecol Obstet. 2019;299(3):675–679. https://doi.org/10.1007/s00404-018-5017-9. Epub 2018 Dec 21. PMID:30,578,439

15.

•• Henkel A, Lerma K, Blumenthal PD, Shaw KA. Evaluation of shorter mifepristone to misoprostol intervals for second trimester medical abortion: a retrospective cohort study. Contraception. 2020 Nov;102(5):327–331. https://doi.org/10.1016/j.contraception.2020.06.009. Epub 2020 Jun 25. PMID:32,592,800. A retrospective review of 89 persons with gestations 15–27 weeks who received misoprostol and mifepristone at different dosing intervals (less than 12 h, 12–24 h, and greater than 24 h) and a subsequent analysis of total induction time as well as total abortion time.

16.

•• Shay RL, Benson LS, Lokken EM, Micks EA. Same-day mifepristone prior to second-trimester induction termination with misoprostol: a retrospective cohort study. Contraception. 2022;107:29–35. https://doi.org/10.1016/j.contraception.2021.09.006. Epub 2021 Sep 13. PMID:34,529,952. A retrospective review of 298 persons with gestations 14–28 weeks who received misoprostol and mifepristone at varying intervals and an analysis of time to fetal expulsion.

17.

Allanson ER, Copson S, Spilsbury K, et al. Pretreatment with mifepristone compared with misoprostol alone for delivery after fetal death between 14 and 28 weeks of gestation: a randomized controlled trial. Obstet Gynecol. 2021;137(5):801–9. https://doi.org/10.1097/AOG.0000000000004344.CrossRefPubMed

18.

Dadhwal V, Garimella S, Khoiwal K, Sharma KA, Perumal V, Deka D. Mifepristone followed by misoprostol or ethacridine lactate and oxytocin for second trimester abortion: a randomized trial. Eurasian J Med. 2019;51(3):262–266. https://doi.org/10.5152/eurasianjmed.2019.18341. Epub 2019 Aug 19. PMID:31,692,613; PMCID:PMC6812907.

19.

Whitehouse KC, Stifani BM, Duffy JMN, Kim CR, Creinin MD, DePiñeres T, Winikoff B, Gemzell-Danielsson K, Blum J, Sherman RB, Lavelanet AF, Brahmi D, Grossman D, Tamang Gebreselassie H, Ponce de Leon RG, Ganatra B. Standardizing abortion research outcomes (STAR): results from an international consensus development study. Contraception. 2021 Nov;104(5):484–491. https://doi.org/10.1016/j.contraception.2021.07.004. Epub 2021 Jul 14. PMID:34,273,335; PMCID:PMC8609158.

20.

National Guideline Alliance (UK). Medical abortion after 24 weeks’ gestation: abortion care: evidence review L. London: National Institute for Health and Care Excellence (NICE); 2019 Sep. PMID:32,813,471.

21.

Valero I, Garcia-Jimenez R, Weber-Fernandez AM, et al. Combination of mifepristone and misoprostol vs misoprostol monotherapy for treatment of second-trimester pregnancy loss. Eur J Contracept Reprod Health Care. 2022;27(4):341–4. https://doi.org/10.1080/13625187.2022.2054982.CrossRefPubMed

Titel: Second Trimester Medication Abortion Regimens and the Mifepristone-Misoprostol Dosing Interval
verfasst von: Emma M. Smith
Katherine Pocius
Jessica Atrio
Publikationsdatum: 06.05.2023
Verlag: Springer US
Erschienen in: Current Obstetrics and Gynecology Reports / Ausgabe 2/2023
Elektronische ISSN: 2161-3303
DOI: https://doi.org/10.1007/s13669-023-00358-7

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Second Trimester Medication Abortion Regimens and the Mifepristone-Misoprostol Dosing Interval

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

Embryotransfer erhöht womöglich Leukämierisiko der Kinder

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Gynäkologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Infertility Treatment in Women with Obesity

An Update on Contraception for Transgender, Non-binary, and Gender-expansive Individuals

Self-Managed Abortion in the United States

Preventing Adverse Cardiovascular Outcomes in Pregnancy Complicated by Obesity

Management of Labor and Delivery to Reduce Risk for Cesarean Birth in Women with Obesity

Congenital Anomalies in Women with Obesity

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

Embryotransfer erhöht womöglich Leukämierisiko der Kinder

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Gynäkologie